AstraZeneca Pharma receives DCGI permission for Symbicort Turbuhaler

16 Jun 2017 Evaluate

AstraZeneca Pharma India has received Import and Market permission in Form 45 (Marketing Authorization) from the Drug Controller General of India (DCGI) for FDC of Budesonide 320 g +Formoterol Fumarate Dihydrate 9 g inhalation powder.

FDC of Budesonide 320 g + Formoterol Fumarate Dihydrate 9 g inhalation powder (Symbicort Turbuhaler 320/9 g) is a product of AstraZeneca global and is indicated in the regular treatment of Asthma where use of combination of inhaled regular corticosteroid & long acting β-agonist is appropriate and patients with moderate to severe COPD with frequent symptoms and a history of exacerbations.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.



Astrazeneca Pharma I Share Price

9211.50 22.60 (0.25%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×